August saw notable funding rounds in health technology, reflecting increased investment in innovative biotech ventures. Royalty Pharma acquired an up-to $950 million royalty interest in Amgen’s lung cancer immunotherapy Imdelltra after its accelerated FDA approval and strong early sales, highlighting immuno-oncology’s market promise. Market dynamics are shifting as generic approvals, clinical trial adjustments, and ongoing competition reshape the commercial landscape for obesity, diabetes, and oncology therapeutics.